4886
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

ASKA Pharmaceutical Holdings Co., Ltd. is a holding company established in 2021 as the parent of Asuka Pharmaceutical. The group operates through four main business segments: pharmaceuticals, animal health, overseas operations, and other services. The pharmaceuticals segment focuses on the manufacturing and sale of human medicines, while the animal health segment produces veterinary drugs and feed additives. The overseas segment handles the production and distribution of human medicines in international markets, and the other segment includes clinical testing and medical devices. Key subsidiaries include Asuka Pharmaceutical, Asuka Pharmaceutical Medical, Asuka Animal Health, Ha Tay Pharmaceutical Joint Stock Company, and Ha Tay Pharmaceutical and Medical Equipment Joint Stock Company.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage aska-pharma-hd.co.jp
Sector Healthcare IR page aska-pharma-hd.co.jp
Tags
human pharmaceuticals, veterinary drugs, feed additives, clinical testing, medical devices, Asuka Pharmaceutical, Asuka Pharmaceutical Medical, Asuka Animal Health, Ha Tay Pharmaceutical Joint Stock Company, Ha Tay Pharmaceutical and Medical Equipment Joint Stock Company
Press page aska-pharma-hd.co.jp/news

Metrics

Valuation  
Market cap ¥ 58.878B
Market cap (USD) $ 367.993M
P/E 11.17
PEG 1.30
P/BV 0.73
P/S 0.82
P/OCF 10.27
P/FCF 12.59
Dividend yield 2.9%
Turnover / mcap —
Returns  
ROE 7.4%
ROI 6.3%
ROIC 5.4%
Profit margin 7.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 8.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 71.127B 64.139B 62.843B 60.461B 56.607B 52.542B 46.706B 48.944B 48.527B 43.215B 42.907B 39.501B
Net profit 5.424B 5.101B 7.545B 4.238B 4.29B 649M 1.744B 2.388B 2.944B 701M 1.193B 495M
Free cash flow 3.429B -1.077B 33M 2.605B 465M -2.55B 154M -668M 11.373B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 2.36K 2.304K 2.22K 1.189K 1.263K 1.098K 1.146K 1.672K 1.633K 1.392K 1.2K 1.037K
Price performance 12m 0.02 0.04 0.87 -0.06 — -0.04 -0.31 0.02 0.17 0.16 0.16 —

Filed figures

Figure Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) — 14.5B 15.2B 15.6B 15.2B 16B
↳ YoY growth +5.1% +2.4% -2.5% +5.5%
Borrowings, current (JPY) — 1.72B 3.44B 4.98B 4.46B 3.27B
Borrowings, non-current (JPY) — 12.3B 9.19B 4.51B 6.44B 8.17B
Cash and deposits (JPY) 10.5B 12.1B 14.5B 13.7B 10.6B 10.1B
Intangible assets (JPY) — 6.18B 4.47B 2.88B 6.99B 8.87B
Net debt (borrowings + leases - cash) (JPY) — 1.94B -1.88B -4.25B 299M 1.31B
Cash flow detail
Operating cash flow (JPY) — 2.84B 3.35B 1.49B 2.49B 6.3B
Purchases of property, plant and equipment (JPY) — -579M -461M -1.32B -2.96B -2.55B
Purchases of intangible assets (JPY) — -1.8B -285M -133M -602M -325M
Change in receivables (cash effect) (JPY) — -1.36B -742M -370M 1.2B -867M
Change in inventories (cash effect) (JPY) — -687M -2.63B -2.71B -2.68B -2.68B
Change in payables (cash effect) (JPY) — 412M -980M 1.49B 339M -1.54B
Dividends paid (cash effect) (JPY) — -398M -452M -792M -1.28B -1.62B
Interest paid (cash effect) (JPY) — -58M -51M -41M -51M -222M
Income taxes paid (cash effect) (JPY) — -1.39B -850M -1.61B -4.03B -241M
Operating cash flow before change in receivables (JPY) — 4.2B 4.09B 1.86B 1.28B 7.17B
Free cash flow (OCF - PPE - intangibles) (JPY) — 465M 2.61B 33M -1.08B 3.43B
Income detail
Research and development expense (JPY) — 3.6B 4.23B 4.73B 7.03B 7.06B
Total comprehensive income (JPY) — 4.98B 5.98B 8.13B 5.22B 6.58B
Comprehensive income to owners (JPY) — 4.98B 5.98B 8.13B 5.22B 6.59B
Provision for credit losses (JPY) — — — — — -23M
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.1%
Reported Nov 8, 2021 Jun 28, 2022 Jun 27, 2023 Jun 25, 2024 Jun 20, 2025 Jun 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2027年3月期 第2四半期決算短信補足資料 Bull 2 Bear 0 Results

Prompts

ASKA Pharmaceutical Holdings Co., Ltd. (ticker 4886), listed in Japan.

Company History

Date Change Detail
— Continues Continues 4514 (EDINET code E00929) as 4886: the same business renamed or reorganised. Its figures from before are this company's.

ETFs Holding ASKA Pharmaceutical Holdings Co., Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.01% 47,100 $ 645.084K Nov 12, 2026
DFIS 0.01% 36,800 $ 504.015K Nov 12, 2026
DXIV 0.00% 700 $ 9,587.24 Nov 12, 2026
DFIC 0.00% 21,900 $ 299.944K Nov 12, 2026
DFAX 0.00% 13,300 $ 182.158K Nov 12, 2026
DFSI 0.00% 900 $ 12.326K Nov 12, 2026
DFAI 0.00% 13,700 $ 187.636K Nov 12, 2026
AVDE 0.00% 3,500 $ 47.638K Nov 16, 2026
AVDV 0.00% 21,800 $ 296.719K Nov 16, 2026
AVDS 0.00% 800 $ 10.889K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
4886 canonical Common share — JP tsej 2,047.00 JPY 2026-09-29
4514 delisted Common share — JP tsej — —